AgeneBio

$5M disclosed across 3 rounds · 2014–2016

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

SA

Sanegene Bio10 shared keywordsSanegeneBio is a biotech company developing RNA interference (RNAi) genetic medicines for obesity, cardiometabolic, and autoimmune diseases. Its LEAD (Ligand and Enhancer Assisted Delivery) platform enables tissue-specific gene silencing in the liver, adipose tissue, muscle, and immune cells via subcutaneous dosing.

BR

Bridgebio7 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

EN

Engage Bio7 shared keywordsEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

CA

CatenaBio7 shared keywordsCatena Biosciences develops therapeutics using its CysTyr conjugation platform to create Multi-Payload Conjugates (MPCs), a next-generation form of antibody-drug conjugate that delivers dual payloads. The company initially targets solid tumors with high unmet medical need.

IN

Indiebio7 shared keywordsIndieBio was a startup accelerator and pre-seed investment program launched by SOSV in San Francisco in 2015, providing on-site bio-labs and funding to science founders across biotech, food, agriculture, industrial decarbonization, AI, therapeutics, and diagnostics. As of 2026 the program was rebranded to SOSV NY and SOSV SF, expanding its focus from bio to broader deep tech.

Companies competing with AgeneBio for the same Google search keywords, organic and paid, via search-intersection analysis.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.